Journal: ACS Synthetic Biology
Article Title: Enhanced Epigenetic Modulation via mRNA-Encapsulated Lipid Nanoparticles Enables Targeted Anti-inflammatory Control
doi: 10.1021/acssynbio.5c00188
Figure Lengend Snippet: Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection of AAV2-mCherry (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).
Article Snippet: The mCherry construct was a premade AAV vector purchased from PackGene Biotech, (ssAAV-CAG-mCherry.WPRE.SV40pA, cat. no. AAV-EA022).
Techniques: Control, Quantitative RT-PCR, Expressing, Immunohistochemical staining, Staining, Negative Control, Enzyme-linked Immunosorbent Assay, Clinical Proteomics